ICARES MedicusROCO:6612 84 Days Payable is 27.17 as of Dec. 2025, which is 35% above its 10-year median of 20.12. GuruFocus rates ROCO:6612 with a GF Score™ of 84/100 and a GF Value™ of NT$189.91 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 796 Medical Devices & Instruments companies, ICARES Medicus ranks worse than 89.57% on this metric.
The historical rank and industry rank for ICARES Medicus's Days Payable or its related term are showing as below:
ROCO:6612'
s Days Payable Range Over the Past 10 Years
Min: 8.95 Med: 20.12 Max: 49.38
Current: 25.15
During the past 13 years, ICARES Medicus's highest Days Payable was 49.38. The lowest was 8.95. And the median was 20.12.
ROCO:6612's Days Payable is ranked worse than 89.57% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs ROCO:6612: 25.15
ICARES Medicus's Days Payable
declined
from Dec. 2024 (37.26) to Dec. 2025 (27.17).
It may suggest that ICARES Medicusaccelerated paying its suppliers.
ICARES Medicus Days Payable Related Terms
ICARES Medicus Days Payable Historical Data
* Premium members only.
The historical data trend for ICARES Medicus's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6612 vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, ICARES Medicus's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICARES Medicus Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICARES Medicus's Days Payable distribution charts can be found below:
* The bar in red indicates where ICARES Medicus's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ICARES Medicus's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICARES Medicus (ROCO:6612) has a Days Payable of 27.17 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ICARES Medicus and its competitors. This is 35% above median its historical median of 20.12. Over the past decade, ICARES Medicus' Days Payable has ranged from 8.95 to 49.38. According to the industry distribution chart, ICARES Medicus ranks #713 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 89.6%.
Is ICARES Medicus' Days Payable too high?
ICARES Medicus' current Days Payable of 27.17 is 35% above median its 10-year median of 20.12. Over the past 10 years, this metric has ranged from a low of 8.95 to a high of 49.38. The Medical Devices & Instruments industry median Days Payable is 67.97. ICARES Medicus' value of 27.17 is 60% below this industry median. Based on the distribution chart, ICARES Medicus ranks #713 out of 796 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ICARES Medicus has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ICARES Medicus' Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, ICARES Medicus ranks #713 out of 796 companies for Days Payable. This places ICARES Medicus in the lower half of its industry. The industry median Days Payable is 67.97. ICARES Medicus' value of 27.17 is 60% below this benchmark. Historically, ICARES Medicus' own Days Payable has ranged from 8.95 to 49.38 over the past decade. While the company's 10-year median is 20.12 vs. the industry median of 67.97, ICARES Medicus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICARES Medicus's current Days Payable of 27.17 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ICARES Medicus and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICARES Medicus's current Days Payable is 27.17, which is 35% above median its own 10-year median of 20.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICARES Medicus stock overvalued right now?
Based on GuruFocus' analysis, ICARES Medicus (ROCO:6612) is currently considered Possible Value Trap. The stock's GF Value™ is NT$189.91, compared to a current price of NT$74.30 — trading 60.9% below its estimated fair value. The current Days Payable is 27.17, which is 35% above median its 10-year median of 20.12 and 60% below the Medical Devices & Instruments industry median of 67.97. ICARES Medicus' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ICARES Medicus (ROCO:6612), the current Days Payable is 27.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICARES Medicus (ROCO:6612) Overvalued in 2026?
Based on GuruFocus' analysis, ICARES Medicus stock appears to be undervalued.
The current stock price of NT$74.30 is trading 60.9% below its estimated GF Value™ of NT$189.91.
GuruFocus considers ICARES Medicus to be Possible Value Trap.
Key valuation signals for ROCO:6612:
Days Payable: 27.17 (35% above median its 10-year median of 20.12)
GF Value™: NT$189.91 vs. price of NT$74.30 (60.9% below fair value)
Industry Position: 60% below the Medical Devices & Instruments median (#713 of 796)
No single metric tells the full story. See the ROCO:6612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices. In addition, it also designs, develops, manufactures, and sells intraocular lenses and nanomedical devices. The company's operating segments are Europe and America, which derive maximum revenue, China, and R.O.C. Geographically, it generates maximum revenue from the United States, followed by Taiwan, Spain, England, Japan, China, Germany, and other countries.
84GF Score
Get the complete analysis for ROCO:6612
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6612 has been successfully added to your 
